CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Remote Electrical Neuromodulation for Migraines

This policy governs coverage and coding for remote electrical neuromodulation (REN) devices (e.g., Nerivio) for acute and preventive treatment of migraine for Medicare Advantage and commercial products offered by Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJun 1, 2026

Next Review DateN/A

Key ActionVerify member benefits and eligibility and confirm DME coverage prior to treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

A4540Covered HCPCS code for REN device

≥8 yrsFDA-cleared age range

Chronic migraine coveredCoverage statement

≤45 minTypical use duration

~15%US migraine prevalence cited

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Recent clinical refs

Coverage Criteria for Remote Electrical Neuromodulation (REN)

Coverage for chronic migraine

Covered when the following high-level conditions are met:

Coverage conditions: Remote electrical neuromodulation (REN) device is being used for chronic migraine.

Policy statement: 'Remote electrical neuromodulation for chronic migraine is covered.'

Benefit eligibility: Member is enrolled in a Medicare Advantage or Commercial product with applicable DME/REN benefits per their Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.

Benefits may vary between groups and contracts; verify member-specific coverage before claim submission.

Nerivio (remote electrical neuromodulation) is contraindicated in patients with uncontrolled epilepsy and in patients with an active implantable medical device (for example, pacemaker, hearing aid implant, or any implanted electronic device). The device has not been evaluated in certain populations including patients with congestive heart failure, severe cardiac or cerebrovascular disease, pregnancy, or children younger than 8 years.

If services are determined to be not medically necessary or are otherwise non-covered benefits under the member’s contract, the provider may not bill or collect payment from the member unless the member was informed in advance and provided written agreement to pay out-of-pocket. Benefits and eligibility are governed by the member’s subscriber agreement, benefit booklet, or employer agreement, which supersede this medical policy.

This policy section does not provide detailed medical necessity criteria for REN; the document states medical criteria: Not applicable.

Coding and Billing

Covered HCPCS CodesHCPCSCovered

A4540

Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm

Provider Actions, Billing Rules, and Prior Authorization

Prior Authorization

Prior authorization: Not applicable for this policy. Verify member-specific DME and contract benefits prior to providing services.

Prior authorization: Not applicable

Note

Verify Member Benefits and Eligibility

Verify member benefits and eligibility before delivering services. Benefits and coverage can vary by group and contract; refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable Durable Medical Equipment (DME) benefits and coverage.

Check Benefit Booklet / Evidence of Coverage / Subscriber Agreement for DME benefits

Step Therapy

Step Therapy Context

Background and Epidemiology

Migraine is a neurologic disease characterized by recurrent moderate-to-severe headaches often accompanied by associated symptoms such as aura, photophobia, phonophobia, and nausea. Clinically, migraine is categorized by attack frequency as episodic (≤14 headache days per month) or chronic (≥15 headache days per month). Remote electrical neuromodulation (REN, e.g., Nerivio) is a wearable, patient‑controlled peripheral nerve stimulator applied to the upper arm that induces conditioned pain modulation and is used as a nonpharmacologic option for acute treatment and, in more recent clearances, for preventive treatment of migraine in appropriate age groups.

Definitions and Device Description

Chronic migraine

Definition (headache days)Chronic migraine: migraine-like or tension-type headache on 15 or more days per month for more than 3 months.

Duration requirementSymptoms present for more than 3 months.

Associated attack frequencyAt least 5 headache attacks meeting episodic migraine criteria (with or without aura) as specified in policy.

Remote electrical neuromodulation (REN) — device description and typical use

Device form factorWearable REN device (Nerivio) worn on the upper arm.

MechanismStimulates peripheral nerves to induce conditioned pain modulation (CPM) via patient‑controlled peripheral nerve stimulation.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyRemote Electrical Neuromodulation for Migraines

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJun 1, 2026

Next Review DateN/A

Key ActionVerify member benefits and eligibility and confirm DME coverage prior to treatment.

SourceLink

On This Page

Step therapy context: Current first-line preventive therapies for migraine are pharmacologic (antiepileptic drugs, beta‑blockers, certain triptans, antidepressants). Remote electrical neuromodulation (REN; e.g., Nerivio) is positioned as an alternative or adjunct to pharmacologic therapies rather than first‑line pharmacologic treatment.

First-line pharmacologic options: divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, timolol; alternatives: amitriptyline, venlafaxine, atenolol, nadolol, frovatriptan, naratriptan, zolmitriptan

Note

Contact for Member-Specific Benefits

Provider actions: For member-specific benefits and eligibility, contact the provider call center. Do not rely solely on this policy to determine coverage or member financial responsibility.

Contact provider call center for member-specific benefit and eligibility information

Billing Rule

Billing and Claim Submission

Billing rule / denial risk: Claims for REN-related devices should be submitted with the appropriate HCPCS code (A4540). Claims submitted using other codes may not be processed as covered; absence of HCPCS A4540 on claims may lead to denial or processing as non-covered.

Submit REN device claims with HCPCS A4540 (Distal transcutaneous electrical nerve stimulator)

Denial Risk

Member Financial Liability

Member financial liability: If services are determined to be not medically necessary or are non‑covered benefits, providers may not charge the member unless the member was informed in advance and agreed in writing to pay out‑of‑pocket. Refer to your participation agreement(s) for applicable provisions.

Do not bill member for non‑covered or not medically necessary services without prior written member agreement

Control interfaceControlled via Bluetooth using the patient’s smartphone or tablet mobile application.

Stimulation parametersPatient-controlled intensity 0–100% corresponding to 0–40 mA of electrical current; instructed to set to strongest level just below perceived pain.

REN — therapy summary and evidence

Therapy summaryREN is a nonpharmacologic, patient‑controlled peripheral nerve stimulation therapy used for acute treatment of migraine; manufacturer indicates it can be used instead of or in addition to medication.

Typical use for acute attacksInitiate at onset of migraine or aura and no later than within 1 hour of onset; device provides stimulation for up to 45 minutes before turning off automatically.

Clinical evidenceMultiple studies and reports cited including randomized and real‑world studies (e.g., Grosberg et al. 2021; Tepper et al. 2023) and coverage‑with‑evidence development (Synowiec et al. 2025).

Guideline referencePediatric acute migraine guideline referenced (AAN/AHS practice guideline update, Oskoui et al.).